GSK’s Promacta deadline also expires
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's PDUFA date also came and went Sept. 19 for Promacta, though not because of strained resources; the missed deadline for eltrombopag is presumably because FDA and GSK are fine-tuning a Risk Evaluation and Mitigation Strategy for the novel drug candidate to treat chronic immune thrombocytopenic purpura (1"The Pink Sheet" DAILY, Sept. 22, 2008). Amgen's NPlate, also indicated for thrombocytopenia, had a similar delay while the REMS was finalized. Analysts said that the missed user fee date was good news for GSK because if the agency had serious concerns it most likely would have issued a complete response letter and not delayed a decision. In May, Promacta received a positive review from the Oncologic Drugs Advisory Committee as a second-line, short-term treatment for ITP, but the panel had reservations about whether the drug would be used for longer term off-label
You may also be interested in...
REMS Likely Holdup For GSK’s Promacta Approval
FDA misses eltrombopag Sept. 19 PDUFA date; analysts draw parallel with Amgen’s Nplate timeline.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.